AMRX Amneal Pharmaceuticals, Inc.
Debt Financing ·
Amneal's subsidiary converted $2.039 billion of term loans into new loans with a lower interest margin and added a $45.2 million term loan. The company estimates about $12 million of annual cash interest savings, and the maturity stays at August 1, 2032.
Amneal will pay $375 million in cash and issue 28,942,108 shares to buy Kashiv BioSciences, and some sellers are affiliates of the Amneal Group. Up to $350 million more depends on US regulatory milestones for Kashiv products.
Amneal Pharmaceuticals LLC cut the interest margin on its term loans by 50 basis points in an amendment dated February 2, 2026, with JPMorgan Chase Bank, N.A. as administrative agent. The company estimates annual cash interest savings of about $11 million, and the loans still mature on August 1, 2032.
Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes retail generics, injectables and biosimilars. Its Specialty segment offers branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Its AvKARE segment distributes pharmaceuticals and other products to the U.S. federal government, retail and institutional markets. The company operates principally in the United States, India and Ireland. CREXONT (carbidopa and levodopa extended release capsules) is indicated in the United States for Parkinson's disease, and IPX203 is licensed to Zambon Biotech S.A. for Europe and to Knight Therapeutics International S.A. for Canada and Latin America. Under a 15-year strategic collaboration with ApiJect Systems, Corp., Amneal is to install and operate manufacturing equipment leased from ApiJect for its blow fill seal delivery systems at its Brookhaven, New York facility. Amneal is also the preferred global supply partner for Metsera's weight loss medicines, and after Pfizer acquired Metsera, Pfizer shortened the term of that agreement.
| Product or program | What it is | Stage |
|---|---|---|
| CREXONT | Carbidopa and levodopa extended release capsules for Parkinson's disease | marketed in the United States |
| IPX203 | Carbidopa and levodopa product licensed for Europe, Canada and Latin America | not approved outside the United States |
| ONGENTYS (opicapone) | Product licensed from BIAL-Portela for U.S. marketing and distribution | |
| Metsera weight loss medicines | Supply partner arrangement with Metsera, Inc. |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $3.02 billion | $2.79 billion |
| Research and development | $186.2 million | $190.7 million |
| Net income (loss) | $72.1 million | -$116.9 million |
| Cash from operations | $340.0 million | $295.1 million |
| Cash and equivalents | $282.0 million | $110.6 million |
Our latest story on this, dated Apr 22, 2026: "Amneal agrees to acquire Kashiv BioSciences for $375,000,000 in cash and 28,942,108 shares". The story links the filing or release it is based on. Read the story.
Amneal Pharmaceuticals, Inc. trades under the ticker AMRX on NASDAQ.
Amneal Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2DT; LS:A2JLMD; LSX:A2JLMD.
The SEC Central Index Key (CIK) for Amneal Pharmaceuticals, Inc. is 1723128. Its filings are on SEC EDGAR.
319,353,919 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Amneal Pharmaceuticals, Inc. under United States.
Our directory classifies Amneal Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Amneal Pharmaceuticals, Inc. is US03168L1052.
aibio.space lists Amneal Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Amneal Pharmaceuticals, Inc. is a diversified global biopharmaceutical company that develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes retail generics, injectables and biosimilars.
CREXONT: Carbidopa and levodopa extended release capsules for Parkinson's disease Stage: marketed in the United States.
IPX203: Carbidopa and levodopa product licensed for Europe, Canada and Latin America Stage: not approved outside the United States.
$3.02 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Amneal Pharmaceuticals, Inc. reported net income of $72.1 million for the fiscal year ended Dec 31, 2025, and generated $340.0 million of cash from operations, per its annual report to the SEC.
$186.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio